Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 05 October 2016 | By Zachary Brennan
The European Directorate for the Quality of Medicines and Healthcare (EDQM) this week announced a new agreement with Japanese authorities to share more information on the outcome of good manufacturing practice (GMP) inspections of manufacturing sites of active pharmaceutical ingredients (APIs) of interest to both Europe and Japan.
The agreement follows the exchange of letters on 13 September 2016 in which Japan’s Pharmaceutical Safety and Environmental Health Bureau of the Ministry of Health, Labour and Welfare (MHLW), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan and the EDQM explain how communications will be improved while respecting the confidentiality of nonpublic information.
Both regulators began sharing such inspection data back in 2013, though mutual recognition agreements date back to 2003. And back in 2012, the European Fine Chemical Group, an industry association of API manufacturers, called for mandatory inspections of all API manufacturing sites through the use of mutual recognition agreements.
The EU and US, meanwhile, are still working on ways they can mutually recognize each other’s GMP inspections.
Emer Cooke, former head of international affairs at the EMA, told Focus in June that both sides have “progressed quicker than we’d expected.”
"FDA observed one audit in 2014 in Sweden, one in Greece in March 2015, one in Germany in May 2015, one in Croatia in June 2015, one in the UK and one in the Czech Republic in November 2015, one in Italy and one in Hungary in November 2015," EMA spokeswoman Marie-Agnes Heine told Focus. "Six additional audits are planned for 2016 (Austria, Estonia, Lithuania, Malta, Romania, Spain), all of which will be observed by FDA. Audits of 12 additional EU countries are planned for 2017."
A major issue for the sharing of any nonpublic information is the question of trade secret information (inspections typically involve specifications of manufacturing equipment and processes for manufacturing drugs that are proprietary information), though there is a provision in the Food and Drug Administration Safety and Innovation Act (FDASIA) from 2012 to allow FDA to share trade secrets with other regulators.
In addition, the EDQM and MHLW signed a 5-year memorandum of cooperation defining measures to strengthen the collaboration between the European and Japanese pharmacopoeias. These include the option of organizing bilateral meetings, workshops and internships between the two and various Japanese regulatory bodies in order to share experiences and information on the development of monographs and methods of testing. To this end, the EDQM and MHLW also agreed to set up an ad hoc Technical Working Group with staff members of the EDQM and Japanese regulatory bodies and relevant experts.
EDQM enhances sharing of information with Japanese regulatory authorities and strengthens collaboration with Japanese Pharmacopoeia
Tags: mutual recognition of GMP inspections, EMA and PMDA, Pharmacopoeia
Regulatory Focus newsletters
All the biggest regulatory news and happenings.